Imunon

Organisation

Trials

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Phase 3, Recruiting, 500 people, 7 Apr 2025
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1/2, Recruiting, 30 people, 22 Feb 2023
NCT04852367
Collaborator, Phase 1, Withdrawn, 0 people, 21 Apr 2021
NCT03393884
Phase 1/2, Active, not recruiting, 130 people, 9 Jan 2018
NCT01464593
Phase 2, Terminated, 2 people, 3 Nov 2011
NCT00036985
Phase 2, Status unknown, 27 Jan 2003

Sources: clinicaltrials.gov

Named in competing interests

A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial
Board or leadership role, 3 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov